Zepbound (Tirzepatide): Complete 2026 Guide
Pricing, coupons, insurance coverage, and access pathways for the FDA-approved GLP-1 weight-loss medication. Verified monthly.
Zepbound (tirzepatide) is Eli Lilly's FDA-approved weekly injectable for chronic weight management. List price is $499 to $1,086 per month. Commercially insured patients can pay as low as $25 per month with the Lilly Savings Card. Uninsured patients pay $299 to $449 per month through LillyDirect Self Pay. Lilly Cares PAP offers free or reduced access for income-qualified patients. Federal plans (Medicare, Medicaid, Tricare) are excluded from manufacturer coupons, but July 2026 Part D changes and the Most-Favored-Nation pricing framework are expected to expand access.
What is Zepbound?
Zepbound is the brand name for tirzepatide when prescribed for weight management. It is a once-weekly subcutaneous injection that activates both GLP-1 and GIP receptors, producing stronger appetite reduction than single-mechanism GLP-1 drugs like Wegovy. FDA approved for adults with BMI 30+, or BMI 27+ with a weight-related comorbidity such as type 2 diabetes, hypertension, or sleep apnea.
Mounjaro is the same molecule (tirzepatide) marketed for type 2 diabetes. Dosing and clinical evidence are essentially identical; the difference is insurance coverage rules tied to FDA-approved indication.
Pricing snapshot
From $25 per month with insurance and a Savings Card, up to $1,086 per month at list price.
Explore the guide
Three dedicated pages cover the details you need: every active coupon, the full cost breakdown, and patient reviews.
Recent pricing news
Three events in the last 5 months changed the Zepbound pricing landscape.
- February 23, 2026
New multi-dose KwikPen launched
Eli Lilly launched a new single-patient-use KwikPen device containing 4 doses in one pen. Available through LillyDirect cash-pay at $299 to $449 depending on dose — the cheapest current self-pay option for higher doses.
- December 1, 2025
Vial pricing reduced
Eli Lilly cut LillyDirect single-dose vial prices. Previous range $349-$499 lowered to current $299-$699 range depending on dose.
- November 6, 2025In progress
Most-Favored-Nation (MFN) pricing framework announced
Federal framework tying U.S. GLP-1 prices to the lowest prices paid in comparable countries. Expected impact: Zepbound could drop to ~$346/month on a government discount platform launching in early-to-mid 2026. Medicare copays capped at $50/month for eligible enrollees as part of this framework.
Status: Announced, implementation in progress. Not yet reflected in point-of-sale pricing.
Frequently asked
The top questions we see about Zepbound access and cost. Full FAQ on the coupon page.
Compare with other GLP-1s
Zepbound is one of several FDA-approved GLP-1 medications. See the equivalent guides for semaglutide brands.
Pricing verified against Lilly's official pricinginfo.lilly.com page, cross-referenced with Noom Med (March 2026), GoodRx, and Drugs.com. We do not accept payment for inclusion in any comparison. Medical content reviewed by Dr. Golsa Gholampour, MD, board-certified in obesity medicine. Quarterly re-verification scheduled.